Skip to the main content.
Facebook Linkedin X

dual spike virus webinar

About This Presentation

Viral clearance studies are essential to biologics development, but traditional single-virus spike studies can slow programs down with added cost, extended timelines, and high material demands.

In this webinar, scientists from KBI Biopharma and Texcell North America introduce a newly published, validated dual virus spike approach that enables XMuLV and MMV to be tested simultaneously in the same load material, with each virus quantified through virus-specific assays.

The result is a smarter, more efficient path to viral clearance studies that helps teams start earlier, reduces execution burden, and potentially takes viral clearance off the critical path to IND submission.

What You Will Learn

  • See how a proven dual virus spike approach can cut time, lower costs, and reduce material demands in viral clearance studies
  • Learn how this approach can support faster early-stage development and help remove viral clearance from the IND critical path
  • Explore how dual spike studies deliver results comparable to traditional single-virus approaches across critical downstream operations

Watch the Webinar Now

Who Should Watch

  • Biopharma executives: See the strategic value of a method that saves time, cost, and material.
  • Process development scientists: Learn how to streamline viral clearance studies with less time and material.
  • CMC and regulatory leaders: Understand how this approach compares to traditional methods and supports faster IND enablement.
  • Technical consultants: Discover a practical innovation for accelerating early-stage biologics development.
  • Anyone seeking smarter study execution: Explore a more efficient viral clearance strategy for early-stage biologics development.

Ma - Mammalian Home-1

Fine tune to your molecule.
Maximize your success.

Full-scope mammalian programs with the depth of experience to make the complex possible

About Our Presenters

Dual Spike LP headshots

Thomas Lindsey

Process Development Scientist II
KBI Biopharma

Thomas Lindsey is a Process Development Scientist II based at KBI Biopharma's Venture Center in Durham, NC. He has been with KBI Biopharma for 8 years and brings over 11 years of experience in the biopharmaceutical industry, driving innovation and collaboration to advance cutting-edge therapies.

Headshots-1

Symya M Chumbris

Director of Technical Acumen
Texcell- North America

Symya Chumbris is a seasoned professional who has been with Texcell-North America, Inc. since 2011. She has over 14 years of experience in viral clearance, virus production, cell culture, and research and development. Her work on the development of a multi-spike assay for viral clearance studies has been published.

Flexible, Knowledgeable, and Proven


About KBI Biopharma

KBI Biopharma is a leading contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry. With a flexible global network and comprehensive capabilities from cell line development through commercial manufacturing, we help innovators scale their biologics programs with confidence.

Science Driven. Customer Focused.